(Q35746806)

10 August 2017

1 reference

title

Psychiatric medication-induced obesity: a review (English)

1 reference

10 August 2017

0 references

Schwartz TL

1

1 reference

10 August 2017

Nihalani N

2

1 reference

10 August 2017

Jindal S

3

1 reference

10 August 2017

Virk S

4

1 reference

10 August 2017

Jones N

5

1 reference

10 August 2017

1 May 2004

1 reference

10 August 2017

1 reference

10 August 2017

5

1 reference

10 August 2017

2

1 reference

10 August 2017

115-121

1 reference

A review of the effect of atypical antipsychotics on weight

10 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Atypical antipsychotics and weight gain--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Body weight changes associated with psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Weight loss associated with olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Long‐term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

A study of quetiapine: efficacy and tolerability in psychotic adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Genetic variants of the serotonin system and weight change during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Clozapine in adolescent inpatients with acute mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Weight gain among schizophrenic patients treated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Chronic imipramine treatment and weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Imipramine and weight gain during the treatment of recurrent depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Mirtazapine versus fluoxetine in the treatment of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Placebo controlled double-blind trial of fluvoxamine maleate in the obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Severe weight gain induced by combination treatment with risperidone and paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Olanzapine versus divalproex in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Treatment of affective disorder and obesity with topiramate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Do obese depressed patients respond to topiramate? A retrospective chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Changes in body weight with chronic, high-dose gabapentin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Weight gain in epileptic patients during treatment with valproic acid: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

Mirtazapine compared with paroxetine in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2004.00139.X

10.1111/J.1467-789X.2004.00139.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference